Celecoxib

證據等級: L5

預測適應症: 10 個

Celecoxib: From Osteoarthritis to Inflammatory Spondylopathy

One-Sentence Summary

Celecoxib (Celebrex®) is a first-in-class selective COX-2 inhibitor with established global indications for osteoarthritis, rheumatoid arthritis, and acute pain management; it is currently not registered in Taiwan. The TxGNN model predicts it may be effective for Inflammatory Spondylopathy (encompassing ankylosing spondylitis and axial spondyloarthritis), with 19 clinical trials and 20 publications currently supporting this direction — including multiple Phase 3 RCTs that have already led to regulatory approval in the United States and European Union.

Quick Overview

Item	Content
Original Indication	Not marketed in Taiwan; globally indicated for osteoarthritis, rheumatoid arthritis, and acute pain
Predicted New Indication	Inflammatory Spondylopathy (Ankylosing Spondylitis / Axial Spondyloarthritis)
TxGNN Prediction Score	99.80%
Evidence Level	L1
TW Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from our database. Based on the extensive published literature included in this evidence pack, Celecoxib is the first and most well-characterized selective cyclooxygenase-2 (COX-2) inhibitor (coxib) to enter clinical practice. It selectively blocks the COX-2 enzyme, reducing the synthesis of prostaglandin E2 (PGE2) and prostacyclin to alleviate inflammation and pain — while largely sparing the gastroprotective COX-1 pathway that conventional NSAIDs suppress.

The core pathology of inflammatory spondylopathy — including ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) — involves TNF-α and IL-17–driven inflammation of the spine and sacroiliac joints, leading to progressive new bone formation and functional restriction. NSAIDs targeting the prostaglandin pathway are the cornerstone of first-line therapy in all major AS/axSpA treatment guidelines. Celecoxib’s selective COX-2 inhibition directly addresses this inflammatory pathway, reducing PGE2-mediated synovial and entheseal inflammation while offering a more favorable gastrointestinal safety profile compared to non-selective NSAIDs.

Critically, a 2025 systematic review (PMID 39757202) identified Celecoxib as the only NSAID proven to inhibit radiographic bone progression in spondyloarthritis — a disease-modifying property beyond simple analgesia, potentially involving Wnt signalling pathway regulation and osteoclast activity suppression. This is not a speculative repurposing proposal: Celecoxib already holds regulatory approval for AS in the United States (FDA), European Union (EMA), and multiple other markets. The TxGNN prediction is best interpreted as a Taiwan market entry opportunity, backed by a robust global evidence base.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00648141	Phase 3	Completed	458	12-week RCT comparing Celecoxib 200 mg QD, 200 mg BID vs Diclofenac 75 mg SR BID in AS; primary efficacy and safety evaluation
NCT00762463	Phase 3	Completed	240	6-week RDB study of Celecoxib vs Diclofenac SR specifically in Chinese AS patients, with 6-week extension phase
NCT02528201	Phase 4	Completed	330	12-week confirmatory RCT comparing Celecoxib 200 mg vs 400 mg QD vs Diclofenac TID in AS
NCT02758782	Phase 4	Completed	156	CONSUL trial: Celecoxib + Golimumab vs Golimumab alone over 2 years; evaluated radiographic spinal progression in r-axSpA
NCT01934933	Phase 4	Completed	150	Etanercept vs Celecoxib vs combined treatment in active AS over 54 weeks; MRI SPARCC score as primary endpoint
NCT03190603	Phase 4	Completed	12	NSAID (including Celecoxib) effects on MRI inflammatory lesions in axSpA; imaging endpoint study
NCT04115098	Phase 2	Terminated	42	N-of-1 trials comparing selective COX-2 vs non-selective COX inhibitors in axSpA; also evaluated HrQOL and proteomic biomarkers
NCT02355236	Phase 4	Unknown	106	RDB multi-center study comparing Naxozol (naproxen+esomeprazole) vs Celecoxib in OA/RA/AS patients; gastroprotection comparison
NCT03473665	Phase 4	Terminated	9	Pilot 6-week RDB trial of 4 different NSAIDs in axSpA; terminated early due to low enrollment
NCT02456363	Phase 2	Unknown	300	Adalimumab + NSAIDs vs Adalimumab monotherapy in AS; Celecoxib used as background NSAID comparator

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39757202	2025	Systematic Review	BMB Reports	Celecoxib is the only NSAID demonstrated to inhibit radiographic bone progression in SpA; investigates unique COX-2–independent mechanism involving Wnt signalling
40028763	2025	Cohort Study	Scand J Rheumatology	Nationwide retrospective cohort comparing CVD and GIB risk between Celecoxib and nsNSAIDs in AS patients; comparable safety profile confirmed
40911151	2025	Umbrella Review	Drugs	Systematic synthesis of meta-analyses on Celecoxib safety across chronic musculoskeletal conditions
38228361	2024	RCT Analysis	Ann Rheum Dis	CONSUL trial results: Celecoxib + Golimumab vs Golimumab alone in r-axSpA; 2-year radiographic spinal progression outcomes
36800138	2023	Comparative RCT	Clin Rheumatology	Imrecoxib vs Celecoxib in axSpA; changes in bone metabolism markers and sacroiliac joint inflammation after treatment
28626213	2017	Comparative RCT	Med Sci Monitor	Imrecoxib vs Celecoxib in axSpA; DKK-1 levels and imaging scores at weeks 4 and 12 (60 patients)
27603385	2016	Population Study	Medicine	Taiwan NHI database study: Celecoxib associated with reduced coronary artery disease risk in AS patients — locally relevant evidence
16960941	2006	RCT	J Rheumatology	Pivotal RCT confirming Celecoxib is efficacious and well-tolerated in treating signs and symptoms of AS
22141388	2011	Review	Drugs	Comprehensive review confirming EU approval for Celecoxib in OA, RA, and AS; clinical evidence synthesis across all indications
32955700	2021	Clinical Study	Irish J Med Sci	Serum IL-1β, IL-6, and IL-17A as predictive biomarkers for clinical response to Celecoxib in AS patients

Taiwan Market Information

No approved products are currently registered in Taiwan (0 registrations). Celecoxib is not marketed in Taiwan.

Global regulatory context: Celecoxib (Celebrex®) holds US FDA approval for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis (≥2 years), and acute pain. EU (EMA) approval covers OA, RA, and AS in adults. These existing regulatory dossiers provide a substantial foundation for a potential Taiwan NDA submission under the 505(b)(2)–equivalent pathway.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Celecoxib holds FDA and EU approval for ankylosing spondylitis, backed by at least two completed Phase 3 RCTs and a 2025 systematic review establishing a unique disease-modifying property (bone progression inhibition) not demonstrated by any other NSAID. The evidence clearly meets the L1 threshold, and a Taiwan NHI population study (PMID 27603385) provides local cardiovascular safety data. This is primarily a regulatory and market-access question for Taiwan, not a de novo repurposing challenge.

To proceed, the following is needed:

File a Taiwan NDA (新藥查驗登記) referencing the existing FDA/EMA approval packages for the AS/axSpA indication
Obtain and review the Taiwan package insert (仿單) to fill the current gaps in key warnings, contraindications, and drug interaction data
Establish a cardiovascular risk monitoring plan consistent with the COX-2 inhibitor drug class safety profile (particularly for patients with pre-existing cardiovascular risk factors)
Confirm the complete drug interaction profile, especially for anticoagulants, ACE inhibitors, diuretics, and methotrexate
Assess current off-label prescribing patterns for Celecoxib in Taiwan to quantify unmet clinical demand and guide market sizing
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.